论文部分内容阅读
目的探讨血清高尔基体蛋白73(GP73)和甲胎蛋白(AFP)在肝细胞癌中的表达及意义。方法收集原发性肝癌(40例,肝癌组)、肝硬化(40例,肝硬化组)、健康体检者(40例,对照组)为研究对象,采用电化学发光法和酶联免疫吸附法(ELISA法)测定血清AFP和GP73含量。结果肝癌组血清AFP(318.27±169.32 ng/ml)和GP73(262.74±168.98μg/L)水平均明显高于肝硬化组(14.93±4.73 ng/ml;92.59±18.64μg/L)和对照组(5.16±1.45 ng/ml;37.04±8.56μg/L),差异有统计学意义(P<0.05)。AFP和GP73联合检测敏感度和特异度(85.0%、97.5%)较AFP单项检测时(52.5%、85.0%)明显提高(P<0.05)。AFP高值组的2年复发率(58.3%)明显高于AFP低值组(44.4%)与AFP阴性组(26.3%),差异有统计学意义(P<0.05)。AFP高值组的术后12个月(58.3%)、24个月生存率(50.0%)明显低于AFP低值组(77.8%、66.7%)与AFP阴性组(84.2%、73.7%),差异有统计学意义(P<0.05)。GP73阳性组的1年复发率(26.7%)、2年复发率(46.7%)明显高于GP73阴性组(10.0%、20.0%)(P<0.05),GP73阳性组的24个月生存率(60.0%)明显低于GP73阴性组(80.0%),差异有统计学意义(P<0.05)。结论 GP73联合AFP检测有可能成为肝癌诊断的重要血清标志物,且两者在患者术后复发及生存率评价方面均有一定的提示作用。
Objective To investigate the expression and significance of serum progesterone-73 (GP73) and alpha-fetoprotein (AFP) in hepatocellular carcinoma. Methods The primary liver cancer (40 cases, liver cancer group), cirrhosis (40 cases, liver cirrhosis group) and healthy subjects (40 cases, control group) were collected for the study. Electrochemiluminescence and enzyme-linked immunosorbent assay (ELISA method) serum AFP and GP73 content. Results The levels of serum AFP (318.27 ± 169.32 ng / ml) and GP73 (262.74 ± 168.98 μg / L) in hepatocellular carcinoma were significantly higher than those in cirrhosis (14.93 ± 4.73 ng / ml; 92.59 ± 18.64 μg / L) 5.16 ± 1.45 ng / ml and 37.04 ± 8.56 μg / L, respectively), the difference was statistically significant (P <0.05). The sensitivity and specificity of combined detection of AFP and GP73 (85.0%, 97.5%) were significantly higher than those of AFP alone (52.5%, 85.0%) (P <0.05). The 2-year recurrence rate (58.3%) in AFP high-value group was significantly higher than that in AFP low-value group (44.4%) and AFP negative group (26.3%), the difference was statistically significant (P <0.05). The AFP high value group was significantly lower than the AFP negative group (77.8%, 66.7%) and AFP negative group (84.2%, 73.7%) at 12 months (58.3%) and 24 months The difference was statistically significant (P <0.05). The one-year recurrence rate (26.7%) and the two-year recurrence rate (46.7%) in GP73 positive group were significantly higher than those in GP73 negative group (10.0%, 20.0%) (P <0.05) 60.0%) was significantly lower than the GP73 negative group (80.0%), the difference was statistically significant (P <0.05). Conclusion GP73 combined with AFP detection may become an important serum marker for the diagnosis of liver cancer, and both of them have certain hints in the postoperative recurrence and survival evaluation.